Sarin Ankit, Samreen Sarah, Moffett Jennifer M, Inga-Zapata Edmundo, Bianco Francesco, Alkhamesi Nawar A, Owen Jacob D, Shahi Niti, DeLong Jonathan C, Stefanidis Dimitrios, Schlachta Christopher M, Sylla Patricia, Azagury Dan E
University of CA - Davis Health, 6th Floor, 2335 Stockton Blvd., Sacramento, CA, 95817, USA.
University of Texas Medical Branch, Galveston, TX, USA.
Surg Endosc. 2024 Dec;38(12):6987-7010. doi: 10.1007/s00464-024-11384-8. Epub 2024 Nov 14.
Robotic surgical procedures continue to increase both in the United States (US) and worldwide. Several novel robotic surgical platforms are under development or undergoing regulatory approval. This review explores robotic platforms that are expected to reach US consumers within the next 2-3 years.
The SAGES Robotic Platforms Working Group identified robotic surgery platforms in various stages of development and selected multi-visceral systems nearing or completing the US Food and Drug Administration (FDA) approval process. We outline key system components including architecture, unique features, development status, regulatory approval, and expected markets.
We identified twenty robotic platforms that met our selection criteria. Ten companies were based in North America, and ten were based in Europe or Asia. Each system is described in detail and key features are summarized in table form for easy comparison.
The emergence of novel robotic surgical platforms represents an important evolution in the growth of minimally invasive surgery. Increased competition has the potential to bring value to surgical patients by stimulating innovation and driving down cost. The impact of these platforms remains to be determined, but the continued growth of robotic surgery seems to be all but assured.
在美国和全球范围内,机器人外科手术的应用持续增加。有几种新型机器人手术平台正在研发或正在接受监管审批。本综述探讨了预计在未来2至3年内面向美国消费者推出的机器人平台。
外科学会机器人平台工作组确定了处于不同开发阶段的机器人手术平台,并挑选了接近或已完成美国食品药品监督管理局(FDA)审批流程的多脏器系统。我们概述了关键系统组件,包括架构、独特功能、开发现状、监管审批情况以及预期市场。
我们确定了20个符合我们选择标准的机器人平台。其中10家公司位于北美,10家位于欧洲或亚洲。每个系统都有详细描述,关键特征以表格形式汇总以便于比较。
新型机器人手术平台的出现代表了微创手术发展中的一个重要演变。竞争加剧有可能通过刺激创新和降低成本为手术患者带来价值。这些平台的影响尚待确定,但机器人手术的持续增长似乎几乎是确定无疑的。